Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
A veteran in cell therapy and oncology commercialisation
Drug formulations and biologics make impressive gains
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
